ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.63
0.12%
US Tech 100
21,156.80
-0.70%
S&P 500
6,101.24
-0.29%
US Dollar vs CAD
1.43724
-0.80%
Bitcoin
101,627.11
-1.01%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Cassava Sciences Inc (SAVA) Share Price

Cassava Sciences Inc

Cassava Sciences Inc (SAVA)

NASDAQ
2.52
-0.01
(-0.40%)
Closed January 26 3:00PM
Delayed by 15 minutes
2.5198
-0.0002
(-0.01%)
After Hours: 6:55PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
2.5198
Bid
2.50
Ask
2.52
Volume
2,213,917
2.47 Day's Range 2.665
2.23 52 Week Range 42.20
Market Cap
121.229M
Previous Close
2.53
Open
2.55
Last Trade
1000
@
2.5198
(formt)
Last Trade Time
Financial Volume
US$ 5,652,791
VWAP
2.5533
Average Volume (3m)
6,208,570
Shares Outstanding
48,110,475
Dividend Yield
-
PE Ratio
-0.01
Earnings Per Share (EPS)
-2.02
Revenue
-
Net Profit
-97.22M

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnosti... Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.cassavasciences.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Cassava Sciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SAVA. The last closing price for Cassava Sciences was US$2.53. Over the last year, Cassava Sciences shares have traded in a share price range of US$ 2.23 to US$ 42.20.

Cassava Sciences currently has 48,110,475 shares outstanding. The market capitalization of Cassava Sciences is US$121.72 million. Cassava Sciences has a price to earnings ratio (PE ratio) of -0.01.

Ask ADVFN Intelligence (AI)

Cassava Sciences (SAVA) Options Flow Summary

SAVA Options Flow

Overall Flow

Bearish

Net Premium

-45k

Calls / Puts

0.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

SAVA Latest News

More News

The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA

The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA PR Newswire NEW YORK, Jan. 23, 2025 NEW...

January 23 2025
PR Newswire (US)

Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More PR Newswire NEW YORK, Jan. 20, 2025 NEW YORK, Jan. 20, 2025...

January 20 2025
PR Newswire (US)

Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact The Gross Law Firm

Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire NEW YORK, Jan. 16, 2025 NEW YORK, Jan. 16, 2025 /PRNewswire/...

January 16 2025
PR Newswire (US)

Contact The Gross Law Firm by February 10, 2025 Deadline to Join Class Action Against Cassava Sciences, Inc.(SAVA)

Contact The Gross Law Firm by February 10, 2025 Deadline to Join Class Action Against Cassava Sciences, Inc.(SAVA) PR Newswire NEW YORK, Jan. 13, 2025 NEW YORK, Jan. 13, 2025 /PRNewswire/ -- The...

January 13 2025
PR Newswire (US)

Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA PR Newswire NEW YORK, Jan. 9, 2025 NEW YORK, Jan. 9, 2025...

January 09 2025
PR Newswire (US)

Form 8-K - Current report

January 07 2025
Edgar (US Regulatory)

Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA PR Newswire NEW YORK, Jan. 6, 2025...

January 06 2025
PR Newswire (US)

Cassava Sciences, Inc. Class Action: The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA

Cassava Sciences, Inc. Class Action: The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA PR...

January 02 2025
PR Newswire (US)

Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact The Gross Law Firm PR Newswire NEW YORK, Dec. 30, 2024 NEW YORK, Dec. 30, 2024 /PRNewswire/...

December 30 2024
PR Newswire (US)

The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline

The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline PR Newswire NEW YORK, Dec. 26, 2024 NEW YORK, Dec. 26, 2024...

December 26 2024
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2002-7.360294117652.722.782.515157692.67329341CS
4-0.0202-0.7952755905512.543.182.2731149822.72240064CS
12-23.2902-90.237117396425.8133.982.2362085706.41132136CS
26-9.4702-78.984153461211.9942.22.23411189013.43799452CS
52-23.7302-90.400761904826.2542.22.23268133114.17071442CS
156-31.4102-92.573533745933.9362.492.23191054822.19508474CS
260-5.2002-67.36010362697.72146.161.11304177533.35694748CS

SAVA - Frequently Asked Questions (FAQ)

What is the current Cassava Sciences share price?
The current share price of Cassava Sciences is US$ 2.5198
How many Cassava Sciences shares are in issue?
Cassava Sciences has 48,110,475 shares in issue
What is the market cap of Cassava Sciences?
The market capitalisation of Cassava Sciences is USD 121.72M
What is the 1 year trading range for Cassava Sciences share price?
Cassava Sciences has traded in the range of US$ 2.23 to US$ 42.20 during the past year
What is the PE ratio of Cassava Sciences?
The price to earnings ratio of Cassava Sciences is -0.01
What is the reporting currency for Cassava Sciences?
Cassava Sciences reports financial results in USD
What is the latest annual profit for Cassava Sciences?
The latest annual profit of Cassava Sciences is USD -97.22M
What is the registered address of Cassava Sciences?
The registered address for Cassava Sciences is CORPORATION TRUST CENTER, 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Cassava Sciences website address?
The website address for Cassava Sciences is www.cassavasciences.com
Which industry sector does Cassava Sciences operate in?
Cassava Sciences operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
EVAXEvaxion Biotech AS
US$ 5.99
(64.56%)
55.41M
ELABPMGC Holdings Inc
US$ 3.0901
(56.07%)
76.48M
PCLAPicoCELA Inc
US$ 4.60
(49.35%)
3.75M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
GODNUGolden Star Acquisition Corporation
US$ 3.11
(-75.82%)
17.51k
GODNGolden Star Acquisition Corporation
US$ 2.93
(-65.67%)
902.76k
NXTTNext Technology Holding Inc
US$ 1.37
(-54.93%)
2.56M
SGLYSingularity Future Technology Ltd
US$ 1.625
(-38.45%)
917.77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90.11
(-38.07%)
8
ACONAclarion Inc
US$ 0.0557
(28.94%)
811.91M
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
RIMEAlgorhythm Holdings Inc
US$ 0.0357
(4.69%)
284.97M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
NVDANVIDIA Corporation
US$ 142.62
(-3.12%)
232.88M

SAVA Discussion

View Posts
Steady_T Steady_T 3 weeks ago
Something's afoot.... I think it's called pump and dump.
👍️ 1 🤣 2
urge2surge urge2surge 3 weeks ago
Nervous? Just the messenger.. Volume suggests something's afoot imo.
Proven?? You sure about that?
💀 1 🤢 1 ☠️ 1
sunspotter sunspotter 3 weeks ago
Why would any proper pharma company buy a scammy company with a drug candidate proven to be ineffective?

I think we can all safely discount those “rumors”.
👍️ 1
urge2surge urge2surge 3 weeks ago
Biogen buyout rumors. Going to be a huge volume day here!
👍️0
urge2surge urge2surge 1 month ago
Keep in mind the grand canyon gap on the chart. The reward to risk here favors upside including fomo momo.
👍️0
urge2surge urge2surge 1 month ago
No ideas on what catalyst could be in play but there's short covering and institutional buying back in. Last day of tax loss selling is also fueling the buys. The obv is clearly indicating accumulations. Just my take
👍️0
ranchhand71 ranchhand71 1 month ago
Or maybe this is year end retail flush dump capitulation… has the company downsized the staff in Austin? Any idea what their next act is?
👍️0
Steady_T Steady_T 1 month ago
Based on what? Short squeeze could be epic here.
👍️0
urge2surge urge2surge 1 month ago
Looks like bottom is in. Short squeeze could be epic here.
👍️0
ranchhand71 ranchhand71 2 months ago
Majority of employees to be laid off?
👍️0
PonkenPlonken PonkenPlonken 2 months ago
Maybe they can save the company by saying they will turn into an AI drug discovery company and put their cash in BTC?
LOL
👍️0
ranchhand71 ranchhand71 2 months ago
Delusional!
👍️ 1
sunspotter sunspotter 2 months ago
Yes, a company founded and run by fraudsters with a drug that doesn’t work.

What could possibly go wrong?
👍️ 1
ttottip ttottip 2 months ago
It's worth it to take a position here. There's a chance for rebound here.
😂 1
ranchhand71 ranchhand71 2 months ago
In SEC 144 filing CFO using Morgan Stanley to sell SAVA stock . Saying he knows no material info!!!! Hmmm..
👍️0
PonkenPlonken PonkenPlonken 2 months ago
You are most welcome.
Maybe he is good at sniffing out security fraudsters and crooks because he knows how to think like them.
Regards...
👍️0
TheFinalCD TheFinalCD 2 months ago
THANKS for the reply

I cant stand that weirdo either

he just happened to make a good call on $SAVA whether it was really him or not

who knows
👍️0
tredenwater2 tredenwater2 2 months ago
What about the director who poured millions into Cassava propping it up when it would crash from bad news? If this was a scam, wouldnt he have known about it?
👍️0
PonkenPlonken PonkenPlonken 2 months ago
That also baffled me. Many smart people had their money tied up here and somehow the share price recovered after the court cases in September. Id love to know more about the why.
They didnt see the forest for all the trees?
👍️0
PonkenPlonken PonkenPlonken 2 months ago
I can only agree. Shkreli still has friends in the industry that likely told him about all of his "DD" that he presented in this rink dink "paper" then earns the laurels.
98% of PH3 Alzheimer trials miss and this one had many sticks in the soup. --> managements history of lying and no peer reviewed literatue backing.
Unbelievable there is this laughable antihero worshipping around his persona. Nothing fabulous about this sociopath.
👍️ 1
Hoskuld Hoskuld 2 months ago
I made the same call repeatedly over the last 2 years but didn't get the love that the convicted fraudster is getting!
👍️ 1
ranchhand71 ranchhand71 2 months ago
How long before indictments of former CEO and his wife? Class action suit? Who sold with inside info this past Friday?
👍️0
TheFinalCD TheFinalCD 2 months ago
I dont like him but he made a good pre P3 call
if somehow it passed P3 it could have went up slot
P3 fail it crashed


Im listening to him talk about shorting MSTR against BTC hedge/arbitrage
https://x.com/i/broadcasts/1LyxBgywQZkKN
👍️0
MartinLutherKing MartinLutherKing 2 months ago
Last call all aboard SAVA FDA fast track status Micro RNA novel prize cancer destruction RNAZ
👍️0
PonkenPlonken PonkenPlonken 2 months ago
When companies split in ways that put them this far above the minimum requirement they usually do so when they expect much more downside and when they want to cater to the low float crowd instead of real investors in the bio space.
👍️0
PonkenPlonken PonkenPlonken 2 months ago
Thank you. Someone forwarded this to me, else i wouldnt have anticipated something like that :)
Im not interested in ESPR right now as its really in no mans land. I dont "hold" many bios at all. The market has been brutal past few months. But there are some 70 stocks i monitor daily for action...
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
$PGHL. Wow! Ran 918% during market hours. AH down 87%.
The opposite of a bear raid.
Prada
9 hours ago

So what happened? I’ll tell you….

Short sellers need only be outside of margin compliance for a fraction of a second for brokers to force automatic buy-ins. Knowing this, offshore scam operators tightly control the float of all these issuers but sometimes leave borrow available to lure in short sellers...

When short sellers bite, the scam operators wash trade a spike in the stock, then keep bid/asks moving during the halt so no unhalt price can be settled upon during regular trading hours. Then, after hours, it unhalts as they rip the price 10x+, causing brokers to force-liquidate accounts that were short. Brokers buy-in to cover the short sales as scam artists sell into the artificially high price.

This can lead to short accounts being wiped out instantly and can even lead to broker losses. The same liquidation scam playbook had been executed previously with other Nasdaq offshore scam tickers such as $ZJYL.
👍️0
dinogreeves dinogreeves 2 months ago
This is terrible

https://finance.yahoo.com/quote/PGHL/
👍️0
dinogreeves dinogreeves 2 months ago
So much for that former insider/fraudster of KBI*O then turned into another turd HYG*N. But altogether, SAVA has been a scam, any public company that works with Maxim is a scam. Period.
👍️ 1
janice shell janice shell 2 months ago
Yes indeed!
👍️0
FACT-MASTER FACT-MASTER 2 months ago
Exactly.

Nice chatting with you Janice.
👍️0
janice shell janice shell 2 months ago
Yes, I was surprised to learn kidney beans are somewhat toxic. Toxic enough that you should never cook them in the water you soaked them in. I wouldn't have known were I not an inveterate reader of packaging.
👍️0
FACT-MASTER FACT-MASTER 2 months ago
Cassava, from what i have seen, is ingrained into the cultures of Mexican / African / South American diets and they are proud of it.

Their persistence, imo comes from a lack of alternatives and again a culture practice of growing a usable and edible product. Visiting some places in Mexico / Brazil you begin to understand people are just in "survival" mode - use what's available.

The toxicity issue is also common in legume crops such as lima / red kidney beans which are also common in these cultural diets.
👍️0
janice shell janice shell 2 months ago
And it was first done by pretty primitive people.
👍️0
nsomniyak nsomniyak 2 months ago
Cocoa beans taste pretty crappy before you run them through a 15 step process to get chocolate...Another case of " how did they get from this raw stuff to that?"
👍️0
janice shell janice shell 2 months ago
Yes, it was an unusual choice of name. Though it's a popular carbohydrate in Central and South America, perhaps the most popular. I've always wondered how many people died before they figured out how to prepare it. And why they were so persistent.
👍️0
FACT-MASTER FACT-MASTER 2 months ago
Interesting, just like cassava, which when raw, contains cyanide and is toxic.

https://www.medicalnewstoday.com/articles/323756#is-it-toxic

The name picked by scammers for scammers - how suitable!

Now let's see , where is cassava grown? Mexico / Costa Rica / South America. Insiders probably went straight to the airport after the reverse split, never to be seen again, unless of couse Karma catches up to them, amen.

Appreciate the "scam force" here on Ihub - H Bear too.
👍️0
janice shell janice shell 2 months ago
Hello again! I found this one remarkable because it was KNOWN that the most important insiders were scammers. And people seem simply to have discounted that, somehow imagining what they produced would be a winner.
👍️0
FACT-MASTER FACT-MASTER 2 months ago
Why, hello janice!

Our paths have not crossed for a long time.

Yes, investors still gett'in burnt, will it ever end !? i think not, even i , have had to learn a few lessons from my foolish juvenile days. (lol)
👍️0
FACT-MASTER FACT-MASTER 2 months ago
Comprende amigo,

"Its possible for mortals to anticipate a partner in a ph1/ph2 company when their data is about to be due and a BP dropped similar but not equal programs recently"

(cost efficient for a BP to partner up with a smaller biotech demonstrating a superior product in the same category)

The reverse can also be true - eg IMTX, BMY drops out of 1 trial, IMA402 p1/p2 results are poor - same press release in that instance. Was suspicion evident in previous trading - i beleive so, however, hindsight is 20/20
👍️0
janice shell janice shell 2 months ago
Seriously, did anyone need Shkreli to tell them it was doomed? The follies of management should have been enough.
👍️ 1
FACT-MASTER FACT-MASTER 2 months ago
Congrats on your short here with SAVA.

Your education paid off big time in this instance!

We should probably discuss ESPR further on that board, of course if you are up to that.
👍️0
FACT-MASTER FACT-MASTER 2 months ago
Reminds me of of ARGS - that was a stinging lesson for me, ouch...still hurts!

Although i feel bad for investors in SAVA, biotech is high risk and that should be understood by all investors. Lawsuit won't help imo, ... prove wrongdoing against forward looking statements, etc, etc, for 5+ years, imo. - only good for the lawyers, imo.

Ref: Argos Therapeutics
👍️0
TheFinalCD TheFinalCD 2 months ago
https://x.com/MartinShkreli/status/1859681514415607930
👍️0
MartinLutherKing MartinLutherKing 2 months ago
You will all kiss my feet brothers make it all back
👍️0
MartinLutherKing MartinLutherKing 2 months ago
Get ready for Fda fast track status for nobel prize micro rna for terminally ill cancer patients
👍️0
MartinLutherKing MartinLutherKing 2 months ago
A reverse split is NOT something directors or management wishes to do — we all hope it won’t be needed. But the Nasdaq Hearings Panel that approved the extension to continue our Nasdaq listing did so on the condition that our shareholders authorize a reverse split — should one be necessary. The reverse split will not be necessary if our stock closes at $1.00 per share or more for any ten-day period prior to December 31, 2024.
👍️0
PonkenPlonken PonkenPlonken 2 months ago
I have never ever in my life seen a great bio with a chart like this.
SCREAMS promotion campaign - which is something you dont do when you have the next greatest thing in oncology.
Now a 1 for 33 is coming??

"The reverse split will reduce the number of shares of common stock outstanding from 17,265,658 shares to approximately 523,202 shares." per their recent PR. They want to cater to the low float crowd.
A more healthy ratio wouldve done it too...
👍️0
MartinLutherKing MartinLutherKing 2 months ago
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
October 23 2024 - 7:00AM


Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase 1 clinical trial has unanimously approved opening of the second cohort of patients based on its favorable review of Cohort 1 safety data. The therapeutic candidate being evaluated, TTX-MC138, is TransCode’s lead candidate designed to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer. All patients in the first cohort remain on study for continued treatment. No significant safety or dose limiting toxicities have been reported. The dose administered to the second cohort will be approximately double the dose administered to the first cohort.
“An SRC is a group of clinicians and experts that oversee the safety of subjects during the conduct of the trial. The SRC makes decisions on whether and how the study should proceed, including dose escalation and de-escalation decisions per the study design. The recommendations of the SRC are used to decide whether a clinical trial should be continued as designed, changed, or terminated,” commented Sue Duggan, TransCode’s Senior Vice President of Operations. Duggan added, “No dose-limiting toxicities were reported in the first cohort of patients treated with TTX-MC138. Eligible subjects may now be scheduled in Cohort 2 for treatment with the next dose level of TTX-MC138.”
👍️0
MartinLutherKing MartinLutherKing 2 months ago
Is FDA And NIH Ascam
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
September 05 2024 - 7:00AM


Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support clinical evaluation of TTX-MC138, TransCode’s lead therapeutic candidate. TransCode has recently activated three clinical trial sites to conduct a Phase I/II clinical trial of TTX-MC138 for the treatment of advanced solid tumors.


The clinical trial is designed to generate critical data to support evaluation of the safety of TTX-MC138. While efficacy of TTX-MC138 is not an endpoint in this trial, the trial may nevertheless provide early evidence of TTX-MC138 clinical activity in patients with metastatic disease. Funds under the grant are expected to be received over two years.

“We are honored that the NIH recognizes and continues to support our mission to advance therapies against metastatic cancer,” said Zdravka Medarova, Ph.D., Chief Scientific Officer of TransCode. “NIH funding is awarded only after rigorous review. We believe that this award attests to the potential impact, novelty, and robustness of the TTX-MC138 clinical development program.”

TTX-MC138 is a first-in-class therapeutic candidate with novel relevance to metastatic disease. Successful clinical development of TTX-MC138 potentially represents a viable treatment option for many patients with metastatic cancer.
👍️0

Your Recent History

NASDAQ
SAVA
Cassava Sciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads